Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059963 · ClinicalTrials.gov registry record
A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
A clinical trial of Colorectal Cancer and Advanced Adenocarcinoma, sponsored by Universal Diagnostics.
- Recruiting
- Registry status
- 12,000
- Enrollment target
- 1
- Study location
NCT06059963 is a study of Colorectal Cancer and Advanced Adenocarcinoma that is actively recruiting participants, run by Universal Diagnostics. The registered enrollment target is 12,000 participants, above the 1,479-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (711% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06059963, a study of Colorectal Cancer and Advanced Adenocarcinoma, is actively recruiting participants, sponsored by Universal Diagnostics.
- RECRUITING
- Registry status
- 12,000 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
Conditions Studied
Interventions
- DEVICE Signal-C™
Study Locations (1)
Virginia
- Gastroenterology Consultants of SW Virginia - Raonoke
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,000 participants |
| Start Date | 2024-01-18 |
| Est. Completion | 2026-12-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06059963
The ClinicalTrials.gov registry entry for NCT06059963 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 12,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,479-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (711% higher). The listed sponsor is Universal Diagnostics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Signal-C™ is the first listed.
NCT06059963 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT06059963 about?
NCT06059963 is a clinical study titled "A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation". To evaluate the performance characteristics of Signal-C™ a plasma circulating free-DNA test, to detect colorectal cancer and advanced precancerous lesions (APL) in an average risk screening population for 45 and over.
What is the current status of trial NCT06059963?
This trial is currently recruiting. The enrollment target is 12,000 participants. The study started on 2024-01-18. Estimated completion is 2026-12-01.
What conditions does trial NCT06059963 study?
This clinical trial studies the following conditions: Colorectal Cancer, Advanced Adenocarcinoma.
What interventions are being tested in trial NCT06059963?
The interventions under investigation include: Signal-C™ (DEVICE).
Who is sponsoring clinical trial NCT06059963?
This trial is sponsored by Universal Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06059963 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.